Skip to main content

Table 1 Demographical and cerebrospinal fluid (CSF) biomarker values in the Montpellier (AD and NAD) and the WUSTL (amyloid (−) and (+)) cohorts. Results are expressed as means ± standard deviations (SDs). Abbreviations: MMSE Mini-Mental State Examination, AD Alzheimer’s disease, NAD non-Alzheimer’s disease; P significance level of the Student’s t test

From: Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification

Montpellier cohort

NAD

n = 40

AD

n = 10

 

Variable

Mean

SD

Mean

SD

P

Age (years)

69.3

12.1

75.7

10.1

0.1330

Sex (% male)

67.5%

–

20.0%

–

0.0070*

MMSE

21.2

6.2

18.5

4.4

0.2112

E_Tau (pg/mL)

260

182

715

304

< 0.0001

E_pT181 (pg/mL)

42.9

24.6

95.8

25.0

< 0.0001

MS_pT181 (fmol/mL)

23.8

13.2

60.2

27.7

< 0.0001

MS_pT217 (fmol/mL)

0.948

1.066

11.740

5.006

< 0.0001

WUSTL cohort

Amyloid (−)

n = 51

Amyloid (+)

n = 33

 

Variable

Mean

SD

Mean

SD

P

Age (years)

62.7

14.3

67.0

16.3

0.2063

Sex (% male)

39.2%

–

57.6%

–

0.1007*

CDR-SB

0.34

1.09

1.77

1.82

0.0004

%E4

17.7%

–

66.7%

–

< 0.0001*

PiB-PET

0.046

0.047

0.670

0.293

< 0.0001

E_pT181 (pg/mL)

47.5

21.5

76.0

25.4

< 0.0001

MS_pT181 (ng/mL)

0.350

0.256

0.596

0.312

< 0.0001

MS_pT217 (ng/mL)

0.057

0.1121

0.202

0.126

< 0.0001

  1. *Chi-squared test for the comparison of two proportions
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193